Genetics & Genomics

Cancer Risks for Men With BRCA1/2 Mutations

genetic cancer syndromes, breast cancer, cancer screening, risk factors, prostate cancer
ONF 2013, 41(1), 99-101. DOI: 10.1188/14.ONF.99-101

Testing for mutations in breast cancer genes 1 and 2 (BRCA1/2) has been available since 1998, but much of the focus of this testing has been on the implications for women (Weitzel, Blazer, MacDonald, Culver, & Offit, 2011). Women who test positive face a lifetime risk of developing breast cancer of about 87% and about 45% for ovarian cancer, and are confronted with decisions about intensive screening or preventing the malignancies with the use of prophylactic surgery (e.g., bilateral mastectomy, bilateral salpingo-oophorectomy). Women and men who are BRCA 1/2 positive also may have an increased risk of pancreatic cancer and melanoma. However, the clinical implications for men who carry these mutations are not as clear (Pal et al., 2013).

Jump to a section


    Euhus, D.M., & Robinson, L. (2013). Genetic predisposition syndromes and their management. Surgical Clinics of North America, 93, 341-362. doi:10.1016/j.suc.2013.01.005
    Lindor, N.M., McMaster, M.L., Lindor, C.J., & Greene, M.H. (2008). Concise handbook of familial cancer susceptibility syndromes: Second edition. Journal of the National Cancer Institute. Monographs, 38, 1-93. doi:10.1093/jncimonographs/lgn001
    Mitra, A.V., Bancroft, E.K., Barbachano, Y., Page, E.C., Foster, C.S., Jameson, C., … Eeles, R.A. (2011). Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU International, 107(1), 28-39. doi:10.1111/j.1464-410X.2010.09648.x
    Mohamad, H.B., & Apffelstaedt, J.P. (2008). Counseling for male BRCA mutation carriers: A review. Breast, 17, 441-450. doi:10.1093/annonc/mdt025
    National Comprehensive Cancer Network. (2012). NCCN Clinical Practice Guidelines in Oncology: Prostate cancer early detection [v.2.2012]. Retrieved from
    National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian [v.4.2013]. Retrieved from
    Pal, T., Vadaparampil, S., Kim, J., Xu, Y., Friedman, S., Narod, S.A., & Metcalfe, K. (2013). Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. Familial Cancer, 12, 615-619. doi:10.1007/s10689-013-9624-0
    Petrucelli, N., Daly, M.B., & Feldman, G.L. (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer. In R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, R.J.H. Smith, & K. Stephens (Eds.), GeneReviews™. Seattle, WA: University of Washington.
    Ruddy, K.J., & Winer, E.P. (2013). Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Annals of Oncology, 24, 1434-1443. doi:10.1093/annonc/mdt025
    Shannon, K.M., & Chittenden, A. (2012). Genetic testing by cancer site: Breast. Cancer Journal, 18, 310-319. doi:310.1097/PPO.1090b1013e318260946f
    Shiloh, S., Dagan, E., Friedman, I., Blank, N., & Friedman, E. (2013). A follow-up study on men tested for BRCA1/BRCA2 mutations: Impacts and coping processes. Psycho-Oncology, 22, 417-425. doi:10.1002/pon.2106
    Thorne, H., Willems, A.J., Niedermayr, E., Hoh, I.M., Li, J., Clouston, D., … Bolton, D. (2011). Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prevention Research, 4, 1002-1010. doi:10.1158/1940-6207.capr-10-0397
    Tryggvadóttir, L., Vidarsdóttir, L., Thorgeirsson, T., Jonasson, J.G., Olafsdóttir, E.J., Olafsdóttir, G.H., … Tulinius, H. (2007). Prostate cancer progression and survival in BRCA2 mutation carriers. Journal of the National Cancer Institute, 99, 929-935. doi:10.1093/jnci/djm005
    Weitzel, J.N., Blazer, K.R., MacDonald, D.J., Culver, J.O., & Offit, K. (2011). Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA: A Cancer Journal for Clinicians, 61, 327-359.